Shots:
- Pfizer has reported data from Cohort 3 of P-III (BREAKWATER) trial, assessing Braftovi (300mg, PO, QD) + cetuximab & FOLFIRI (n=73) vs FOLFIRI ± Avastin (n=74) in pts with previously untreated BRAF V600E-mutated mCRC
- In Cohort 3, the combination improved ORR (64.4% vs 39.2%), with 57.4% vs 34.5% achieving ≥6mos. responses; mDoR was not estimable for both arms, OS was descriptive (mFU of ~10mos. for both arms)
- Results were presented at the ASCO GI’26, plus the BREAKWATER trial remains ongoing, with completion expected in 2027
Ref: Pfizer | Image: Pfizer | Press Release
Related News: Cartography Biosciences and Pfizer Forge ~$865M Deal for Discovery of Tumor-Selective Antigens
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
